News
The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.
8h
News-Medical.Net on MSNStudy reveals a unique vulnerability in melanoma patients with neurofibromin 1 mutationsIncreased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...
Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.
The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...
6d
SurvivorNet on MSNTargeted Drug Tagrisso Leads To More Tumor Shrinkage For Lung Cancer Patients With EGFR Mutation: Unpacking The New DataPatients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...
In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...
Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...
New findings from the CONFIDENCE trial show that combination therapy with finerenone and empagliflozin leads to significantly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results